SCHEDULE: Federated Hermes Reports 13.15% Stake in Forte Bio

Federated Hermes, Inc., along with its affiliates and the Donahue family, disclosed a 13.15% beneficial ownership stake in Forte Biosciences, Inc. common stock.

Summary

• Federated Hermes, Inc. and related entities, including the Voting Shares Irrevocable Trust and the Donahue family, collectively reported beneficial ownership of 1,635,380 shares of Forte Biosciences, Inc. common stock.
• This aggregate ownership represents 13.15% of Forte Biosciences' outstanding common stock.
• The shares are held by registered investment companies and separate accounts advised by subsidiaries of Federated Hermes, Inc.
• The reporting persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Forte Biosciences, Inc., except for activities solely in connection with a nomination under Rule 14a-11.
• The reporting persons expressly disclaim beneficial ownership of the reported securities.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding Forte Biosciences' operational or financial performance. The presence of a large institutional investor could be seen as a neutral to slightly positive signal.

Positives

• A significant institutional investor, Federated Hermes, holds a substantial stake (13.15%) in Forte Biosciences, which may signal institutional confidence in the company.

Negatives

• The filing itself does not contain negative information regarding Forte Biosciences' operations or financial performance.

Risks

• The reporting persons explicitly disclaim beneficial ownership of the reported securities, which clarifies their legal position but does not imply a risk to Forte Biosciences.

Future Outlook

This filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding Forte Biosciences' future performance or operations.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
• The Parent, the Trust, and each of the Trustees declare that this statement should not be construed as an admission that they are the beneficial owners of the Reported Securities, and the Parent, the Trust, and each of the Trustees expressly disclaim beneficial ownership of the Reported Securities.

Industry Context

The disclosure of a significant stake by a major investment manager like Federated Hermes is a routine event in the financial industry, reflecting institutional portfolio management activities. Such filings provide transparency into large ownership positions, which can be particularly relevant for smaller-cap companies like those often found in the biotechnology sector, where institutional backing can be a key indicator.

Corporate Governance

Related Party Transactions

• The Donahue family (Thomas R., Ann C., and J. Christopher Donahue) are trustees of the Voting Shares Irrevocable Trust, which holds all outstanding voting stock of Federated Hermes, Inc., establishing a control relationship over the reporting entity.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder, which can influence market perception and liquidity.
• Management: Awareness of a large, passive institutional investor on the shareholder register.

Key Dates

Keywords

Forte Biosciences, Federated Hermes, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Equity Stake, Investment Management